This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celera, Merck Ink R&D Deal

Celera (CRA), a molecular diagnostics unit of Applera (ABI), will collaborate with Merck (MRK - Get Report) to develop companion tests for cancer therapies.

Financial terms of the deal were not disclosed. According to the agreement, Celera will evaluate the use of gene expression profiles after which the companies plan to use the diagnostic predictors in Merck's clinical trials to establish commercial companion tests for oncology therapies.

Merck will pay Celera an undisclosed amount for the collaboration, which the companies said they expect to be completed by the end of Celera's fiscal 2008. Also, if Merck transfers one of the gene expression profiles that Celera validated to a clinical reference laboratory, Celera is eligible for an additional payment.

Celera shares edged up 11 cents, or 0.8%, to $13.27, and Merck was down 40 cents, or 0.8%, at $49.14. Applera was 24 cents, or 0.7%, higher at $33.24.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABI $22.98 1.01%
MRK $54.71 -1.80%
AAPL $93.03 -1.90%
FB $116.50 -0.20%
GOOG $690.63 -0.06%


Chart of I:DJI
DOW 17,689.65 -141.11 -0.79%
S&P 500 2,056.73 -19.08 -0.92%
NASDAQ 4,760.8580 -44.4330 -0.92%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs